A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity

Trial Profile

A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs LOXO 292 (Primary)
  • Indications Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 27 Nov 2017 Planned patient number changed to 180.
    • 02 Nov 2017 According to a Loxo Oncology media release, data from the study has been presented at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer.
    • 02 Nov 2017 According to a Loxo Oncology media release, company will provide a study update in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top